Listing of Alligator Bioscience AB on Nasdaq Stockholm
Alligator Bioscience AB (“Alligator” or the “Company”), a leading biotech company developing innovative immune activating antibody drugs for tumor-directed immunotherapy, announced on November 2, 2016 its intention to list the Company’s shares on Nasdaq Stockholm. Today, the Company publishes the prospectus for the offering (the “Offering”).
The offering in summary
|Price interval||32,50 SEK per share|
|Application period for the public in Sweden||15 November – 22 November 2016|
|Application period for institutional investors||15 November – 22 November 2016|
|First day of trading||23 November 2016|
|Settlement date||25 November 2016|